Home » Stocks » Invitae Corporation

Invitae Corporation (NVTA)

Stock Price: $30.95 USD 1.19 (4.00%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
Pre-market: $31.33 +0.38 (1.23%) Aug 14, 9:06 AM

Stock Price Chart

Key Info

Market Cap 4.08B
Revenue (ttm) 233.24M
Net Income (ttm) -420.54M
Shares Out 131.79M
EPS (ttm) -4.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $30.95
Previous Close $29.76
Change ($) 1.19
Change (%) 4.00%
Day's Open 29.91
Day's Range 29.79 - 31.59
Day's Volume 2,249,033
52-Week Range 7.42 - 35.33

More Stats

Market Cap 4.08B
Enterprise Value 3.98B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 131.79M
Float 109.56M
EPS (basic) -3.9
EPS (diluted) -4.02
FCF / Share -1.77
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 19.69M
Short Ratio 8.51
Short % of Float 15.01%
Beta 2.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 17.49
PB Ratio 8.45
Revenue 233.24M
Operating Income -395.89M
Net Income -420.54M
Free Cash Flow -228.79M
Net Cash 102.06M
Net Cash / Share 0.77
Gross Margin 42.33%
Operating Margin -169.74%
Profit Margin -180.30%
FCF Margin -98.10%
ROA -29.40%
ROE -104.39%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 4
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(5.49% upside)
Current: $30.95
Target: 32.65
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth46.8%116.5%172.36%198.97%422.32%983.78%--
Gross Profit98.7267.5918.08-2.83-8.15-4.02-0.52-
Operating Income-244-123-121-100-89.48-47.35-24.75-8.56
Net Income-242-129-123-100-89.78-47.49-24.99-8.60
Shares Outstanding90.8666.7546.5133.1828.210.850.690.64
Earnings Per Share-2.66-1.94-2.65-3.02-3.18-56.14-36.13-14.18
Operating Cash Flow-145-92.22-97.98-76.32-80.66-42.44-23.03-9.15
Capital Expenditures-20.05-5.97-6.68-11.63-6.46-6.69-4.52-0.77
Free Cash Flow-165-98.19-105-87.94-87.12-49.13-27.55-9.92
Cash & Equivalents39813270.0797.3213210743.1921.86
Total Debt31977.7944.5013.6810.203.542.001.22
Net Cash / Debt79.1854.1025.5783.6412210441.1920.65
Book Value38016212299.07138-83.58-37.28-12.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Invitae Corporation
Country United States
Employees 1,500
CEO Sean Emerson George

Stock Information

Ticker Symbol NVTA
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: NVTA
IPO Date February 12, 2015


Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.